VitaSpring Biomedical Co. Ltd. VSBC
OTC PK
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 63.27% | 9.70% | -36.77% | 15.42% | -54.69% |
| Depreciation & Amortization | -- | -- | 0.00% | 0.00% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 63.27% | 9.70% | -36.05% | 15.10% | -54.69% |
| Operating Income | -63.27% | -9.70% | 36.05% | -15.10% | 54.69% |
| Income Before Tax | -57.21% | -9.70% | 35.57% | -15.10% | 54.69% |
| Income Tax Expenses | -- | -- | -100.00% | -91.33% | -- |
| Earnings from Continuing Operations | -40.61% | 5.84% | 43.05% | 27.41% | 49.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.61% | 5.84% | 43.05% | 27.41% | 49.34% |
| EBIT | -63.27% | -9.70% | 36.05% | -15.10% | 54.69% |
| EBITDA | -65.84% | -10.04% | 36.77% | -15.42% | 55.32% |
| EPS Basic | -60.00% | 0.00% | 42.86% | 22.22% | 54.55% |
| Normalized Basic EPS | -66.67% | 0.00% | 50.00% | 0.00% | 57.14% |
| EPS Diluted | -60.00% | 0.00% | 42.86% | 22.22% | 54.55% |
| Normalized Diluted EPS | -66.67% | 0.00% | 50.00% | 0.00% | 57.14% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |